ASX · PME.AX
Pro Medicus Limited
A$197.75+A$0.66 (+0.33%)
Pro Medicus Limited’s quoted price sits in the upper half of its reported 52-week range, 27.52% below the high.
Loading market information…
ASX · ALC.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 04:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Alcidion Group Limited’s quoted price sits in the lower half of its reported 52-week range, 24.14% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Alcidion Group Limited’s next earnings report is currently expected on Feb 25, 2027, with estimated earnings per share of A$0.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Alcidion Group Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Alcidion Group Limited operates as a healthcare technology firm, specializing in the creation and licensing of software products across Australia, New Zealand, and the United Kingdom. Its flagship product, Miya Precision, is a consolidated platform built on the Fast Healthcare Interoperability Resources (FHIR) standard, aimed at enabling intelligent healthcare delivery. The company also supplies Smartpage, a mobile and web-based system designed to streamline hospital communications and task management for clinical and administrative personnel. Additional solutions include Patientrack, a tool for real-time patient monitoring and risk screening; Silverlink, which handles patient administration; and ExtraMed, software dedicated to optimizing clinical and patient flow. Furthermore, Alcidion provides a range of services encompassing product deployment, support and maintenance, systems integration, and data analysis. Founded in 2000 and headquartered in South Yarra, Australia, the company was formerly known as Alcidion Corporation Pty Ltd until its rebranding as Alcidion Group Limited in December 2015.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:29 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2024 | Feb 27, 2024 | -A$0.00-240.0% vs estimate | A$19.06M-9.67% vs estimate |
|---|
| Q4 2023 | Aug 24, 2023 | -A$0.00+40.0% vs estimate | A$21.40M+2.39% vs estimate |
|---|
| Q2 2023 | Feb 23, 2023 | -A$0.00 | A$18.98M-17.46% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$197.75+A$0.66 (+0.33%)
Pro Medicus Limited’s quoted price sits in the upper half of its reported 52-week range, 27.52% below the high.
A$2.80+A$0.07 (+2.56%)
Artrya Limited’s quoted price sits in the lower half of its reported 52-week range, 56.86% below the high.
$0.15$0.00 (0.0%)
Oneview Healthcare PLC’s quoted price sits in the lower half of its reported 52-week range, 6.25% below the high.
A$0.18+A$0.00 (0.0%)
Singular Health Group Ltd’s quoted price sits in the lower half of its reported 52-week range, 40.0% below the high.
A$0.07+A$0.00 (0.0%)
Resonance Health Limited’s quoted price sits in the upper half of its reported 52-week range, 13.95% below the high.
A$0.07+A$0.00 (+4.23%)
Beamtree Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 67.11% below the high.
A$0.02A$0.00 (0.0%)
Pathkey.AI Ltd’s quoted price sits in the lower half of its reported 52-week range, 78.67% below the high.
A$0.08+A$0.01 (+8.57%)
PainChek Limited’s quoted price sits in the lower half of its reported 52-week range, 84.8% below the high.
